US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Neumora Therapeutics, Inc.

0.7569

-0.0425-5.32%

Post-market: 0.76020.0033+0.44%19:46 EDT

Volume:10.85M

Turnover:8.24M

Market Cap:122.43M

PE:-0.47

High:0.8174

Open:0.7911

Low:0.7569

Close:0.7994

Loading ...

Overview Company News Filings

RBC Downgrades Neumora Therapeutics to Sector Perform From Outperform, Price Target is $4

MT Newswires Live

RBC downgrades Neumora Therapeutics to Sector Perform after trial failure

Neumora Therapeutics downgraded to Sector Perform from Outperform at RBC Capital

Neumora Stock Dives After Study Failure -- WSJ

Neumora Therapeutics shares plunge as depression treatment misses trial targets

Neumora Therapeutics Stock Tanks as Its Depression Drug Misses Goals

BUZZ-Neumora hits record low as depression drug fails in late-stage study

Neumora Therapeutics' stock craters after trial of major depressive disorder fails to meet main goals

Stock in Biotech Neumora Plunges 80% as Depression Drug Fails -- Barrons.com

Neumora Therapeutics Inc trading resumes

Optimistic Buy Rating for Neumora Therapeutics Despite Recent Clinical Setback

Neumora Therapeutics Inc trading halted, volatility trading pause

Neumora Therapeutics Price Target Maintained With a $23.00/Share by Needham

Neumora Shares Down 82.5% After Co's Depression Drug Fails to Meet Main Goal in a Late-Stage Trial

THOMSON REUTERS

Neumora trial failure a ‘big blow’ to bull case, says Stifel

Sector Update: Health Care Stocks Edge Higher Premarket Thursday

MT Newswires Live

Morning Movers: Neumora Therapeutics plummets after KOASTAL-1 misses endpoint

Wall Street Kicks Off 2025 in Upbeat Mood, Lifting US Equity Futures

MT Newswires Live

Neumora Therapeutics Depression Drug Fails In First Of Three Pivotal Phase 3 Trials

Neumora Therapeutics: Untapped Potential Amidst Ongoing Trials and Anticipated Positive Developments

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/NMRA/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NMRA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NMRA\",,,,,undefined,":{"symbol":"NMRA","market":"US","secType":"STK","nameCN":"Neumora Therapeutics, Inc.","latestPrice":0.7569,"timestamp":1751054400000,"preClose":0.7994,"halted":0,"volume":10854038,"hourTrading":{"tag":"盘后","latestPrice":0.7602,"preClose":0.7569,"latestTime":"19:46 EDT","volume":3355195,"amount":2540536.976486,"timestamp":1751067986090},"delay":0,"floatShares":85865485,"shares":161747922,"eps":-1.610306,"marketStatus":"Market Closed","change":-0.0425,"latestTime":"06-27 16:00:00 EDT","open":0.7911,"high":0.8174,"low":0.7569,"amount":8242902.701012201,"amplitude":0.075682,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.610306,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1751270400000},"marketStatusCode":7,"adr":0,"listingDate":1694750400000,"exchange":"NASDAQ","adjPreClose":0.7994,"preHourTrading":{"tag":"盘前","latestPrice":0.8001,"preClose":0.7994,"latestTime":"09:21 EDT","volume":106,"amount":87.9336038,"timestamp":1751030514999},"postHourTrading":{"tag":"盘后","latestPrice":0.7602,"preClose":0.7569,"latestTime":"19:46 EDT","volume":3355195,"amount":2540536.976486,"timestamp":1751067986090},"volumeRatio":16.693809193630077,"impliedVol":3.0628,"impliedVolPercentile":0.824},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NMRA\",,,,,undefined,":{"symbol":"NMRA","floatShares":85865485,"roa":"-48.50%","roe":"-79.05%","lyrEps":-1.529624,"volumeRatio":16.693809193630077,"shares":161747922,"dividePrice":0,"high":0.8174,"amplitude":0.075682,"preClose":0.7994,"low":0.7569,"week52Low":0.611,"pbRate":"0.54","week52High":17.1874,"institutionHeld":0,"latestPrice":0.7569,"eps":-1.610306,"divideRate":0,"volume":10854038,"delay":0,"ttmEps":-1.610306,"open":0.7911,"prevYearClose":10.6,"prevWeekClose":0.7857,"prevMonthClose":0.7163,"prevQuarterClose":1,"fiveDayClose":0.7857,"twentyDayClose":0.7187,"sixtyDayClose":0.9133},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NMRA\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2500167976","title":"RBC Downgrades Neumora Therapeutics to Sector Perform From Outperform, Price Target is $4","url":"https://stock-news.laohu8.com/highlight/detail?id=2500167976","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500167976?lang=en_us&edition=fundamental","pubTime":"2025-01-03 00:14","pubTimestamp":1735834465,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics (NMRA) has an average rating of buy and mean price target of $23.49, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from majo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","NMRA"],"gpt_icon":0},{"id":"2500761919","title":"RBC downgrades Neumora Therapeutics to Sector Perform after trial failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2500761919","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500761919?lang=en_us&edition=fundamental","pubTime":"2025-01-03 00:10","pubTimestamp":1735834212,"startTime":"0","endTime":"0","summary":"RBC Capital downgraded Neumora Therapeutics (NMRA) to Sector Perform from Outperform with a price target of $4, down from $29, following lead drug ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rbc-downgrades-neumora-therapeutics-to-sector-perform-after-trial-failure?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rbc-downgrades-neumora-therapeutics-to-sector-perform-after-trial-failure?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","NMRA"],"gpt_icon":0},{"id":"2500976116","title":"Neumora Therapeutics downgraded to Sector Perform from Outperform at RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2500976116","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500976116?lang=en_us&edition=fundamental","pubTime":"2025-01-03 00:05","pubTimestamp":1735833924,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Brian Abrahams downgraded Neumora Therapeutics (NMRA) to Sector Perform from Outperform with a price target of $4, down from $2...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neumora-therapeutics-downgraded-to-sector-perform-from-outperform-at-rbc-capital?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neumora-therapeutics-downgraded-to-sector-perform-from-outperform-at-rbc-capital?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","NMRA"],"gpt_icon":0},{"id":"2500032975","title":"Neumora Stock Dives After Study Failure -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2500032975","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500032975?lang=en_us&edition=fundamental","pubTime":"2025-01-03 00:03","pubTimestamp":1735833780,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics shares plunged more than 80% on Thursday after its lead drug candidate failed to help patients with depression in a study.The drug, called navacaprant, was no better than a placebo in the trial, the first of three Phase 3 studies the company is running in hopes of gaining U.S. approval.\"Today's readout represents a worst-case scenario for the program,\" said RBC Capital Markets analyst Brian Abrahams in a note to clients.Neumora shares fell 81% to $2.00 in early trading.The company said it has cash of $342 million that will allow it to survive into at least mid-2026.This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL .","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NMRA"],"gpt_icon":0},{"id":"2500973021","title":"Neumora Therapeutics shares plunge as depression treatment misses trial targets","url":"https://stock-news.laohu8.com/highlight/detail?id=2500973021","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500973021?lang=en_us&edition=fundamental","pubTime":"2025-01-02 23:48","pubTimestamp":1735832880,"startTime":"0","endTime":"0","summary":"This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","NMRA","BK4139"],"gpt_icon":0},{"id":"2500455976","title":"Neumora Therapeutics Stock Tanks as Its Depression Drug Misses Goals","url":"https://stock-news.laohu8.com/highlight/detail?id=2500455976","media":"Investopedia","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500455976?lang=en_us&edition=fundamental","pubTime":"2025-01-02 23:47","pubTimestamp":1735832826,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics reported its experimental depression drug didn't meet expectations, and shares plunged.The biopharmaceutical firm's navacaprant treatment failed to reach both primary and secondary endpoints.The company said it would continue to investigate the results and provide more information at a conference later this month.Neumora Therapeutics  shares crashed 80% to an all-time low Thursday when the biopharmaceutical firm announced that a late-stage study of its experimental treatment for depression did not meet its goals.The company reported that in the first of three Phase 3 trials, the drug navacaprant \"did not demonstrate a statistically significant improvement on the primary endpoint of change from baseline in the Montgomery-sberg Depression Rating Scale  total score at Week 6 or the key secondary endpoint of a change from baseline in the Snaith-Hamilton Pleasure Scale  scale.\". Rob Lenz, the head of research and development at Neumora, said the company was \"disappointe","market":"fut","thumbnail":"https://www.investopedia.com/thmb/rj1RgFv5qLpw76mwTohdhJs0Cng=/4927x3284/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-2167102223-b3724671abba400daaa8415a07f41ac2.jpg","type":0,"news_type":0,"thumbnails":["https://www.investopedia.com/thmb/rj1RgFv5qLpw76mwTohdhJs0Cng=/4927x3284/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-2167102223-b3724671abba400daaa8415a07f41ac2.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investopedia.com/neumora-therapeutics-stock-tanks-as-its-depression-drug-misses-goals-8768109","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investopedia_highlight","symbols":["LENZ","BK4007","NMRA","BK4139"],"gpt_icon":0},{"id":"2500973102","title":"BUZZ-Neumora hits record low as depression drug fails in late-stage study","url":"https://stock-news.laohu8.com/highlight/detail?id=2500973102","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500973102?lang=en_us&edition=fundamental","pubTime":"2025-01-02 23:42","pubTimestamp":1735832538,"startTime":"0","endTime":"0","summary":"BUZZ-Neumora hits record low as depression drug fails in late-stage studyUpdates** Drug developer Neumora Therapeutics' NMRA.O shares fall 80% to $2.08, hitting lowest level since its Nasdaq debut. ** Stock on track for biggest one-day percentage fall since debut if losses hold. ** NMRA says its experimental depression drug, navacaprant, did not meet the main goal in a late-stage trial** The drug did not reduce symptoms of depression as measured on a disease severity scale that tracks sadness, reduced sleep and pessimistic thoughts** NMRA says the drug also did not improve anhedonia, a patients' inability to feel pleasure — a key secondary goal in the study** Brokerage RBC Capital Markets says results \"represent a worst-case scenario for the program\". ** Brokerage Needham says data \"reduces the likelihood\" of the drug succeeding in two other late-stage studies. ** NMRA plans to discuss updates on development of the drug at an industry conference later this month. ** Co says its cash ba","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250102:nL4N3NY0LY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NMRA"],"gpt_icon":0},{"id":"2500978408","title":"Neumora Therapeutics' stock craters after trial of major depressive disorder fails to meet main goals","url":"https://stock-news.laohu8.com/highlight/detail?id=2500978408","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500978408?lang=en_us&edition=fundamental","pubTime":"2025-01-02 23:27","pubTimestamp":1735831620,"startTime":"0","endTime":"0","summary":"News is a setback for the clinical-stage biotech and a drug that proved successful in earlier trials. Neumora Therapeutics Inc.'s stock tumbled 80% Thursday, after the clinical-stage biotech said a late-stage trial of a treatment for major depressive disorder failed to meet its main goals.The Watertown, Mass.-based company  said the Phase 3 trial of navacaprant failed to demonstrate statistically significant improvement on the primary endpoint of reduction in depressive symptom compared to placebo at week 6.Navacaprant is the company's main product candidate, and was measured using the Montgomery-sberg Depression Rating Scale, or MADRS, a 10-question diagnostic questionnaire used by mental-health professionals to measure the severity of depressive symptoms.The treatment did show an efficacy signal in women, however and the company will further analyze the data, he said.\"There is a lot to investigate from this study, in particular the contrast in drug and placebo responses in depressed ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4007","NMRA","BK4139","ABVC"],"gpt_icon":0},{"id":"2500920883","title":"Stock in Biotech Neumora Plunges 80% as Depression Drug Fails -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2500920883","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500920883?lang=en_us&edition=fundamental","pubTime":"2025-01-02 22:59","pubTimestamp":1735829940,"startTime":"0","endTime":"0","summary":"Shares of the biotech Neumora Therapeutics began the first trading day of 2025 with a loss of more than 80% after the company said that its experimental depression drug failed in a key trial.Patients who received the drug, called navacaprant, showed no more improvement in depressive symptoms than people who received a placebo. The Phase 3 trial was the first of three that were intended to pave the way for the drug's approval as a treatment for major depressive disorder.But there is still hope for Neumora, which has no approved drug in its portfolio. Navacaprant could perform better in the two continuing Phase 3 trials. And while navacaprant is Neumora's lead pipeline asset, the company has a handful of other drugs in earlier phases of testing.Neumora said Thursday that it has enough cash on hand to operate through the middle of 2026.For male participants, however, the drug appeared to work worse than the placebo. Male participants saw a 10.6-point reduction on navacaprant, and a 13.8-p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NMRA","BK4007"],"gpt_icon":0},{"id":"2500927441","title":"Neumora Therapeutics Inc trading resumes","url":"https://stock-news.laohu8.com/highlight/detail?id=2500927441","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500927441?lang=en_us&edition=fundamental","pubTime":"2025-01-02 22:41","pubTimestamp":1735828866,"startTime":"0","endTime":"0","summary":"09:39 EST Neumora Therapeutics (NMRA) Inc trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking fin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neumora-therapeutics-inc-trading-resumes?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neumora-therapeutics-inc-trading-resumes?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","NMRA","BK4007","BK4139"],"gpt_icon":0},{"id":"2500922988","title":"Optimistic Buy Rating for Neumora Therapeutics Despite Recent Clinical Setback","url":"https://stock-news.laohu8.com/highlight/detail?id=2500922988","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500922988?lang=en_us&edition=fundamental","pubTime":"2025-01-02 22:35","pubTimestamp":1735828516,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Paul Matteis has maintained their bullish stance on NMRA stock, giving a Buy rating today. Paul Matteis has given his Buy r...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/optimistic-buy-rating-for-neumora-therapeutics-despite-recent-clinical-setback?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/optimistic-buy-rating-for-neumora-therapeutics-despite-recent-clinical-setback?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","NMRA"],"gpt_icon":0},{"id":"2500092250","title":"Neumora Therapeutics Inc trading halted, volatility trading pause","url":"https://stock-news.laohu8.com/highlight/detail?id=2500092250","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500092250?lang=en_us&edition=fundamental","pubTime":"2025-01-02 22:35","pubTimestamp":1735828510,"startTime":"0","endTime":"0","summary":"09:34 EST Neumora Therapeutics (NMRA) Inc trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, m...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neumora-therapeutics-inc-trading-halted-volatility-trading-pause?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neumora-therapeutics-inc-trading-halted-volatility-trading-pause?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","NMRA","BK4007","BK4139"],"gpt_icon":0},{"id":"2500922855","title":"Neumora Therapeutics Price Target Maintained With a $23.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2500922855","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500922855?lang=en_us&edition=fundamental","pubTime":"2025-01-02 22:33","pubTimestamp":1735828380,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NMRA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 02, 2025 09:33 ET (14:33 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NMRA","LENZ"],"gpt_icon":0},{"id":"2500041924","title":"Neumora Shares Down 82.5% After Co's Depression Drug Fails to Meet Main Goal in a Late-Stage Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2500041924","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500041924?lang=en_us&edition=fundamental","pubTime":"2025-01-02 22:31","pubTimestamp":1735828313,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250102:nL4N3NY0LG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NMRA"],"gpt_icon":0},{"id":"2500922543","title":"Neumora trial failure a ‘big blow’ to bull case, says Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2500922543","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500922543?lang=en_us&edition=fundamental","pubTime":"2025-01-02 22:20","pubTimestamp":1735827613,"startTime":"0","endTime":"0","summary":"After Neumora Therapeutics (NMRA) announced the Phase 3 KOASTAL-1 Study of navacaprant for the treatment of major depressive disorder did not demon...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neumora-trial-failure-a-big-blow-to-bull-case-says-stifel?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neumora-trial-failure-a-big-blow-to-bull-case-says-stifel?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NMRA","SF","BK4007","BK4127"],"gpt_icon":0},{"id":"2500000921","title":"Sector Update: Health Care Stocks Edge Higher Premarket Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=2500000921","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500000921?lang=en_us&edition=fundamental","pubTime":"2025-01-02 22:12","pubTimestamp":1735827162,"startTime":"0","endTime":"0","summary":"Health care stocks were edging higher premarket Thursday, with the iShares Biotechnology ETF  and The Health Care Select Sector SPDR Fund  up 0.6%.Neumora Therapeutics  shares were down more than 82% after the company said that the phase 3 KOASTAL-1 study of navacaprant in treating major depressive disorder failed to meet its primary endpoint.Hutchmed   shares were up more than 5% after the company said overnight that the China National Medical Products Administration has accepted and granted priority review to its New Drug Application for the combination of Orpathys and Tagrisso for the treatment of patients with a specific type of non-small cell lung cancer.ANI Pharmaceuticals  shares were up over 4% after the company said it has launched its prucalopride tablets, the generic version of Motegrity, after receiving final approval from the US Food and Drug Administration.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4581","BK4531","BK4585","NMRA","XLV","IBB","BK4007","ANIP","HCM","BK4588"],"gpt_icon":0},{"id":"2500392454","title":"Morning Movers: Neumora Therapeutics plummets after KOASTAL-1 misses endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2500392454","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500392454?lang=en_us&edition=fundamental","pubTime":"2025-01-02 22:00","pubTimestamp":1735826437,"startTime":"0","endTime":"0","summary":"Check out this morning’s top movers from around Wall Street, compiled by The Fly.  HIGHER – Topgolf Callaway (MODG) up 8% after Jefferies upgr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/morning-movers-neumora-therapeutics-plummets-after-koastal-1-misses-endpoint?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/morning-movers-neumora-therapeutics-plummets-after-koastal-1-misses-endpoint?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MODG","BK4007","BK4139","BK4190","NMRA","LENZ"],"gpt_icon":0},{"id":"2500929292","title":"Wall Street Kicks Off 2025 in Upbeat Mood, Lifting US Equity Futures","url":"https://stock-news.laohu8.com/highlight/detail?id=2500929292","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500929292?lang=en_us&edition=fundamental","pubTime":"2025-01-02 21:53","pubTimestamp":1735825987,"startTime":"0","endTime":"0","summary":"US equity futures rose ahead of Thursday's opening bell to begin 2025 in an upbeat mood as traders digested jobless claims data.Dow Jones Industrial Average futures rose 0.7%, S&P 500 futures increase","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["QLD","DDM","QID","USJW.SI","TSYW.SI","BK4554","NVIW.SI","TQQQ","BK4588","NET","MNQmain",".IXIC","NMRA","SDOW","UDOW","DOG","BK4007","BK4116","BK4548","BK7016","PSQ",".SPX","USAW.SI","DXD","BK4215","BK4560","SQQQ","DJX","LU2286300806.USD","NQmain","EQR","BK4585","NET.AU",".DJI"],"gpt_icon":1},{"id":"2500929163","title":"Neumora Therapeutics Depression Drug Fails In First Of Three Pivotal Phase 3 Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2500929163","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500929163?lang=en_us&edition=fundamental","pubTime":"2025-01-02 21:30","pubTimestamp":1735824628,"startTime":"0","endTime":"0","summary":"On Thursday,Neumora Therapeutics, Inc. stock traded lower after the company released data from the Phase 3 KOASTAL-1 Study of navacaprant for major depressive disorder.The KOASTAL-1 Study is the first of three replicate Phase 3 studies that comprise the pivotal KOASTAL program.The study did not demonstrate a statistically significant improvement on the primary endpoint of change from baseline in the Montgomery-sberg Depression Rating Scale  total score at Week 6 or the key secondary endpoint of a change from baseline in the Snaith-Hamilton Pleasure Scale  scale.Also Read: Why Is Neurology Focused-Neumora Therapeutics Shares Trading Lower On Monday?“We are disappointed by the results from KOASTAL-1 as they were not consistent with the body of evidence supporting this mechanism in MDD. There is a lot to investigate from this study, in particular the contrast in drug and placebo responses in depressed mood and anhedonia in female participants compared to male participants,” said Rob Lenz,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neumora-therapeutics-depression-drug-fails-133028449.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","NMRA","BK4007","BK4139"],"gpt_icon":0},{"id":"2500926707","title":"Neumora Therapeutics: Untapped Potential Amidst Ongoing Trials and Anticipated Positive Developments","url":"https://stock-news.laohu8.com/highlight/detail?id=2500926707","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500926707?lang=en_us&edition=fundamental","pubTime":"2025-01-02 21:25","pubTimestamp":1735824313,"startTime":"0","endTime":"0","summary":"Needham analyst Ami Fadia maintained a Buy rating on Neumora Therapeutics, Inc. (NMRA – Research Report) today and set a price target of $23.00. Am...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/neumora-therapeutics-untapped-potential-amidst-ongoing-trials-and-anticipated-positive-developments?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/neumora-therapeutics-untapped-potential-amidst-ongoing-trials-and-anticipated-positive-developments?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NMRA","LENZ","BK4139","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":5,"totalSize":111,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NMRA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-12","symbol":"NMRA","fiscalQuarterEnding":"2025/03","expectedEps":-0.4,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747022400000,"reportTimeType":"post","actualEps":-0.42},{"market":"US","date":"2024-11-12","symbol":"NMRA","fiscalQuarterEnding":"2024/09","expectedEps":-0.38,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-0.45}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NMRA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NMRA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.375,"hold":0.625,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.625,"analysts":8,"updateTime":1743566400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NMRA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NMRA","date":"2025-06-27","current":-0.501055,"percent":0.906921,"low":-19.620035,"twenty":-11.897527,"median":-6.552046,"eighty":-0.939895,"high":-0.385538,"avg":-7.16271,"sd":5.251111,"marketCap":129301288},"quantilePoints":[{"date":"2023-09-15","current":-19.620035,"twenty":-19.620035,"median":-19.620035,"eighty":-19.620035,"marketCap":2583134632},{"date":"2023-09-22","current":-12.753675,"twenty":-18.754446,"median":-15.453663,"eighty":-12.753675,"marketCap":1679123396},{"date":"2023-09-28","current":-13.691957,"twenty":-17.415667,"median":-13.628246,"eighty":-12.772209,"marketCap":1802655635},{"date":"2023-10-05","current":-13.813351,"twenty":-16.65135,"median":-13.723658,"eighty":-12.773914,"marketCap":1818638110},{"date":"2023-10-13","current":-11.180579,"twenty":-14.994038,"median":-13.691957,"eighty":-12.763183,"marketCap":1472012710},{"date":"2023-10-20","current":-11.493728,"twenty":-13.94093,"median":-13.080265,"eighty":-11.639864,"marketCap":1513241282},{"date":"2023-10-27","current":-14.254079,"twenty":-14.080107,"median":-13.080265,"eighty":-11.690896,"marketCap":1876663508},{"date":"2023-11-03","current":-10.734234,"twenty":-13.848145,"median":-12.776843,"eighty":-11.493728,"marketCap":1667466680},{"date":"2023-11-10","current":-10.420012,"twenty":-13.826354,"median":-12.7442,"eighty":-11.403032,"marketCap":1618655149},{"date":"2023-11-17","current":-11.79624,"twenty":-13.813351,"median":-12.154821,"eighty":-11.403032,"marketCap":1832439792},{"date":"2023-11-24","current":-11.717599,"twenty":-13.766958,"median":-11.806071,"eighty":-11.438475,"marketCap":1820223526},{"date":"2023-12-01","current":-12.041995,"twenty":-13.704638,"median":-11.815901,"eighty":-11.48267,"marketCap":1870615621},{"date":"2023-12-08","current":-12.26809,"twenty":-13.59002,"median":-11.825731,"eighty":-11.493283,"marketCap":1905737383},{"date":"2023-12-15","current":-14.381583,"twenty":-13.717318,"median":-11.894542,"eighty":-11.493728,"marketCap":2234049513},{"date":"2023-12-22","current":-13.75245,"twenty":-13.821153,"median":-12.041995,"eighty":-11.521564,"marketCap":2136319390},{"date":"2023-12-29","current":-16.848963,"twenty":-14.008036,"median":-12.137729,"eighty":-11.563317,"marketCap":2617334836},{"date":"2024-01-05","current":-16.111698,"twenty":-14.24211,"median":-12.26809,"eighty":-11.573312,"marketCap":2502807349},{"date":"2024-01-12","current":-14.991056,"twenty":-14.660761,"median":-12.728927,"eighty":-11.585874,"marketCap":2328725569},{"date":"2024-01-19","current":-14.411074,"twenty":-14.428768,"median":-12.751722,"eighty":-11.613398,"marketCap":2238630612},{"date":"2024-01-26","current":-14.843603,"twenty":-15.020547,"median":-12.776843,"eighty":-11.648787,"marketCap":2305820071},{"date":"2024-02-02","current":-14.991056,"twenty":-15.264335,"median":-13.370218,"eighty":-11.652719,"marketCap":2328725569},{"date":"2024-02-09","current":-17.1537,"twenty":-15.346909,"median":-13.691957,"eighty":-11.671529,"marketCap":2664672864},{"date":"2024-02-16","current":-18.490607,"twenty":-15.539581,"median":-13.783396,"eighty":-11.691031,"marketCap":2872349373},{"date":"2024-02-23","current":-18.500437,"twenty":-15.932789,"median":-13.819852,"eighty":-11.69454,"marketCap":2873876407},{"date":"2024-03-01","current":-17.330643,"twenty":-16.668088,"median":-13.939224,"eighty":-11.709735,"marketCap":2692159461},{"date":"2024-03-08","current":-12.297819,"twenty":-16.990518,"median":-13.97363,"eighty":-11.717599,"marketCap":2901363004},{"date":"2024-03-15","current":-10.189453,"twenty":-16.81554,"median":-13.826354,"eighty":-11.69454,"marketCap":2403946708},{"date":"2024-03-22","current":-9.414974,"twenty":-16.668088,"median":-13.783396,"eighty":-11.650753,"marketCap":2221227691},{"date":"2024-03-28","current":-8.492333,"twenty":-16.613039,"median":-13.722203,"eighty":-11.579976,"marketCap":2003553733},{"date":"2024-04-05","current":-9.246609,"twenty":-16.364935,"median":-13.534996,"eighty":-11.491504,"marketCap":2181506166},{"date":"2024-04-12","current":-9.435178,"twenty":-16.111698,"median":-12.865966,"eighty":-11.216259,"marketCap":2225994275},{"date":"2024-04-19","current":-7.105005,"twenty":-15.954415,"median":-12.753675,"eighty":-10.606446,"marketCap":1676248365},{"date":"2024-04-26","current":-6.123304,"twenty":-15.846283,"median":-12.728927,"eighty":-10.162515,"marketCap":1444640411},{"date":"2024-05-03","current":-6.231441,"twenty":-15.669339,"median":-12.297819,"eighty":-9.792112,"marketCap":1470152824},{"date":"2024-05-10","current":-6.135514,"twenty":-15.610358,"median":-12.155389,"eighty":-9.435178,"marketCap":1558549450},{"date":"2024-05-17","current":-6.047595,"twenty":-15.433415,"median":-12.120637,"eighty":-9.273547,"marketCap":1536216091},{"date":"2024-05-24","current":-5.846636,"twenty":-15.423584,"median":-11.91675,"eighty":-8.957021,"marketCap":1485168412},{"date":"2024-05-31","current":-6.085275,"twenty":-15.399992,"median":-11.884712,"eighty":-8.469435,"marketCap":1545787530},{"date":"2024-06-07","current":-6.235993,"twenty":-15.362637,"median":-11.806071,"eighty":-7.09423,"marketCap":1584073290},{"date":"2024-06-14","current":-6.248553,"twenty":-15.342977,"median":-11.75692,"eighty":-6.904314,"marketCap":1587263770},{"date":"2024-06-21","current":-5.557759,"twenty":-15.335113,"median":-11.717599,"eighty":-6.419582,"marketCap":1411787373},{"date":"2024-06-28","current":-5.777557,"twenty":-15.335113,"median":-11.707769,"eighty":-6.279953,"marketCap":1467620772},{"date":"2024-07-05","current":-6.129234,"twenty":-15.228947,"median":-11.690896,"eighty":-6.264891,"marketCap":1556954210},{"date":"2024-07-12","current":-7.253346,"twenty":-15.12278,"median":-11.653703,"eighty":-6.277441,"marketCap":1842502165},{"date":"2024-07-15","current":-6.939348,"twenty":-15.110984,"median":-11.648787,"eighty":-6.278697,"marketCap":1762740166},{"date":"2024-08-02","current":-7.931581,"twenty":-15.099188,"median":-11.648787,"eighty":-6.279953,"marketCap":2014788082},{"date":"2024-08-09","current":-6.56038,"twenty":-15.040207,"median":-11.579976,"eighty":-6.279953,"marketCap":1798711865},{"date":"2024-08-16","current":-6.881395,"twenty":-14.991056,"median":-11.493728,"eighty":-6.279953,"marketCap":1886727125},{"date":"2024-08-23","current":-6.712133,"twenty":-14.991056,"median":-11.447336,"eighty":-6.393648,"marketCap":1840319079},{"date":"2024-08-30","current":-6.54287,"twenty":-14.922244,"median":-11.299816,"eighty":-6.436952,"marketCap":1793911032},{"date":"2024-09-06","current":-6.297731,"twenty":-14.859331,"median":-10.957407,"eighty":-6.374465,"marketCap":1726699379},{"date":"2024-09-13","current":-6.904742,"twenty":-14.68632,"median":-10.606446,"eighty":-6.374465,"marketCap":1893128235},{"date":"2024-09-20","current":-7.430039,"twenty":-14.481851,"median":-10.304733,"eighty":-6.410301,"marketCap":2037153206},{"date":"2024-09-27","current":-7.634321,"twenty":-14.416972,"median":-9.973946,"eighty":-6.432454,"marketCap":2093162917},{"date":"2024-10-04","current":-7.905725,"twenty":-14.387481,"median":-9.835887,"eighty":-6.454177,"marketCap":2167575819},{"date":"2024-10-11","current":-8.988421,"twenty":-14.365855,"median":-9.536197,"eighty":-6.471402,"marketCap":2464427288},{"date":"2024-10-18","current":-9.898936,"twenty":-14.275648,"median":-9.492422,"eighty":-6.494727,"marketCap":2714070572},{"date":"2024-10-25","current":-7.587628,"twenty":-14.23812,"median":-9.435178,"eighty":-6.5109,"marketCap":2080360698},{"date":"2024-10-31","current":-7.126534,"twenty":-14.186945,"median":-9.414974,"eighty":-6.517189,"marketCap":1953938778},{"date":"2024-11-08","current":-7.599301,"twenty":-14.11026,"median":-9.329429,"eighty":-6.519524,"marketCap":2083561252},{"date":"2024-11-15","current":-6.430581,"twenty":-14.036864,"median":-9.246609,"eighty":-6.508113,"marketCap":1888648838},{"date":"2024-11-22","current":-5.330396,"twenty":-14.008036,"median":-9.078889,"eighty":-6.434404,"marketCap":1565526710},{"date":"2024-11-29","current":-5.467919,"twenty":-13.980511,"median":-8.972721,"eighty":-6.336098,"marketCap":1605916976},{"date":"2024-12-06","current":-5.313893,"twenty":-13.902792,"median":-8.614876,"eighty":-6.276185,"marketCap":1560679878},{"date":"2024-12-13","current":-5.819979,"twenty":-13.839429,"median":-8.495238,"eighty":-6.248553,"marketCap":1709316057},{"date":"2024-12-20","current":-5.775971,"twenty":-13.821153,"median":-8.377845,"eighty":-6.222869,"marketCap":1696391172},{"date":"2024-12-27","current":-6.238049,"twenty":-13.812967,"median":-8.200475,"eighty":-6.175381,"marketCap":1832102465},{"date":"2025-01-03","current":-1.083682,"twenty":-13.811432,"median":-8.147945,"eighty":-6.157876,"marketCap":318275296},{"date":"2025-01-10","current":-1.303719,"twenty":-13.766574,"median":-7.931581,"eighty":-6.140538,"marketCap":382899721},{"date":"2025-01-17","current":-1.193701,"twenty":-13.753032,"median":-7.891133,"eighty":-6.119668,"marketCap":350587508},{"date":"2025-01-24","current":-1.1882,"twenty":-13.716154,"median":-7.812392,"eighty":-6.085275,"marketCap":348971898},{"date":"2025-01-31","current":-1.056178,"twenty":-13.615504,"median":-7.634321,"eighty":-6.067691,"marketCap":310197242},{"date":"2025-02-07","current":-1.07268,"twenty":-13.546812,"median":-7.564281,"eighty":-5.978405,"marketCap":315044074},{"date":"2025-02-14","current":-0.929656,"twenty":-13.337262,"median":-7.53602,"eighty":-5.966304,"marketCap":273038198},{"date":"2025-02-21","current":-0.940658,"twenty":-13.1053,"median":-7.470895,"eighty":-5.920328,"marketCap":276269419},{"date":"2025-02-28","current":-0.852643,"twenty":-12.883791,"median":-7.424202,"eighty":-5.847483,"marketCap":250419649},{"date":"2025-03-07","current":-1.009931,"twenty":-12.773914,"median":-7.253346,"eighty":-5.800175,"marketCap":246207962},{"date":"2025-03-14","current":-0.930199,"twenty":-12.763183,"median":-7.144044,"eighty":-5.763741,"marketCap":226770492},{"date":"2025-03-21","current":-0.770737,"twenty":-12.752113,"median":-7.105005,"eighty":-5.687956,"marketCap":187895550},{"date":"2025-03-28","current":-0.730871,"twenty":-12.743752,"median":-7.036301,"eighty":-5.574632,"marketCap":178176815},{"date":"2025-04-04","current":-0.564099,"twenty":-12.730087,"median":-6.998128,"eighty":-5.417311,"marketCap":137520105},{"date":"2025-04-11","current":-0.476129,"twenty":-12.580434,"median":-6.945391,"eighty":-5.374404,"marketCap":116074096},{"date":"2025-04-17","current":-0.41859,"twenty":-12.352677,"median":-6.926527,"eighty":-5.321594,"marketCap":102046721},{"date":"2025-04-25","current":-0.497989,"twenty":-12.291873,"median":-6.904742,"eighty":-1.375231,"marketCap":121403202},{"date":"2025-05-02","current":-0.511809,"twenty":-12.245663,"median":-6.881395,"eighty":-1.223405,"marketCap":124772347},{"date":"2025-05-09","current":-0.423699,"twenty":-12.15573,"median":-6.846375,"eighty":-1.1893,"marketCap":103292222},{"date":"2025-05-16","current":-0.417316,"twenty":-12.148314,"median":-6.834702,"eighty":-1.12879,"marketCap":107691766},{"date":"2025-05-23","current":-0.449909,"twenty":-12.121955,"median":-6.75723,"eighty":-1.07488,"marketCap":116102658},{"date":"2025-05-30","current":-0.450473,"twenty":-12.120637,"median":-6.747152,"eighty":-1.061679,"marketCap":116248231},{"date":"2025-06-06","current":-0.507762,"twenty":-12.041995,"median":-6.685868,"eighty":-1.033834,"marketCap":131031991},{"date":"2025-06-13","current":-0.562731,"twenty":-11.924033,"median":-6.5954,"eighty":-0.989998,"marketCap":145217284},{"date":"2025-06-20","current":-0.488895,"twenty":-11.91238,"median":-6.57789,"eighty":-0.951354,"marketCap":126163379},{"date":"2025-06-27","current":-0.501055,"twenty":-11.897527,"median":-6.552046,"eighty":-0.939895,"marketCap":129301288}],"updateTime":1751146815668}}}